Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab + Chemotherapy in Advanced Cervical Cancer
NCT03556839Phase 3Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Sep 2018
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoints: Progression-Free Survival at 48 months and Overall Survival at 48 months. Started Sep 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03556839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556839.